Synergistic killing of human leukemia cells by antioxidants and trichostatin A

Jiuhong Kang1, Jie Chen, Dawei Zhang

  • 1School of Life Sciences, Lanzhou University, Lanzhou, China. kangjiuhong@lzu.edu.cn

Abstract

Insights

Combining antioxidants like ascorbic acid (AA) and N-acetyl-cysteine (NAC) with trichostatin A (TSA) enhances anticancer effects in human leukemia cells. This combination therapy shows greater efficacy than individual treatments by targeting both reactive oxygen species and histone acetylation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Antioxidants and trichostatin A (TSA) are recognized for their individual anticancer properties.
  • These agents are thought to combat cancer through distinct mechanisms.
  • Investigating synergistic effects is crucial for developing novel chemotherapy strategies.

Purpose of the Study:

  • To evaluate the combined anticancer efficacy of antioxidants (ascorbic acid, AA; N-acetyl-cysteine, NAC) and TSA in human leukemia (HL-60) cells.
  • To determine if combining these agents enhances neoplastic toxicity compared to monotherapy.
  • To explore the underlying mechanisms of action for the combination therapy.

Main Methods:

  • HL-60 cells were treated with varying doses of AA, NAC, TSA, or their combinations.
  • Cell proliferation arrest, lactate dehydrogenase (LDH) release, and cell viability were assessed.
  • Reactive oxygen species (ROS) accumulation and histone acetylation levels were measured.

Main Results:

  • Both antioxidants (AA, NAC) and TSA demonstrated dose- and time-dependent cytotoxicity.
  • Antioxidants reduced ROS generation but did not affect histone acetylation.
  • TSA increased histone acetylation without affecting ROS generation.
  • The combination therapy significantly enhanced cytotoxicity, reduced ROS, and increased histone acetylation.

Conclusions:

  • Combining antioxidants with TSA amplifies their anticancer effects in HL-60 leukemia cells.
  • This synergistic approach offers a promising strategy for developing novel anticancer drugs.
  • Targeting both ROS and histone acetylation represents a potential dual-action chemotherapy mechanism.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...